Welcome to our dedicated page for Addus Homecare SEC filings (Ticker: ADUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Addus HomeCare Corporation files regulatory documents that reveal how government reimbursement rates, state Medicaid budgets, and healthcare policy changes affect its three business segments. For a company where Medicaid and Medicare represent the primary revenue sources, SEC filings offer direct insight into the regulatory dynamics that shape financial performance.
The company's 10-K annual reports break down revenue by segment, showing how personal care, hospice, and home health each contribute to the business. These filings detail the states where Addus operates, payor concentration by government program, and the impact of reimbursement rate changes on margins. Healthcare investors following home-based care providers will find segment-level profitability data essential for understanding the business mix.
Quarterly 10-Q filings track how state Medicaid budget decisions flow through to revenue, particularly important given the company's dependence on government payors. These reports also show acquisition activity as Addus has historically grown through M&A, with each deal adding new service territories and payor relationships.
Form 4 insider transactions track when executives and directors buy or sell shares. For a healthcare services company operating in a heavily regulated industry, insider activity can signal management confidence around rate negotiations and policy developments.
Material event filings (8-K) capture acquisition announcements, leadership changes, and developments in key state markets. Our AI-powered summaries highlight the essential details from these filings, saving you from parsing lengthy legal disclosures to find the information that matters.
Proxy statements (DEF 14A) detail executive compensation structures, which in healthcare services often tie to patient outcomes and operational metrics alongside financial targets.
Addus HomeCare Corp director Esteban Lopez reported selling a total of 150 shares of the company’s common stock on 12/15/2025. The Form 4 discloses two separate sales: 50 shares at a price of $114.55 and 100 shares at $115.50, each recorded as a disposition of common stock. After these transactions, Lopez beneficially owns 3,700 shares of Addus HomeCare common stock in direct ownership.
Addus HomeCare Corp executive Darby Anderson, EVP and Chief Government Relations Officer, reported an option exercise and share sale. On 11/19/2025, Anderson exercised 20,000 employee stock options at an exercise price of $22.70 per share, acquiring the same number of Addus HomeCare common shares. On the same date, Anderson sold 20,000 common shares at a price of $109 per share.
After these transactions, Anderson directly beneficially owned 44,144 shares of Addus HomeCare common stock, and held 0 remaining employee stock options. The filing notes that all options involved in this transaction were fully vested.
Addus HomeCare (ADUS) reported solid Q3 2025 growth, with net service revenues of $362.3 million, up from $289.8 million a year ago. Operating income rose to $32.9 million from $26.0 million, and net income increased to $22.8 million from $20.2 million. Diluted EPS was $1.24 versus $1.10.
Growth was broad-based: personal care delivered $275.8 million, hospice $68.9 million, and home health $17.6 million. For the first nine months, revenue reached $1.05 billion (from $857.5 million), with net income of $66.1 million (from $54.1 million) and diluted EPS of $3.60 (from $3.17). Cash from operations was $92.7 million.
Addus completed the Helping Hands acquisition on August 1 for approximately $21.4 million, adding $3.1 million of quarterly revenue and $0.4 million of operating income. The company continued to streamline its portfolio, progressing on the New York asset sale and recording $3.8 million in deferred payments year-to-date, with $2.3 million remaining as of September 30, 2025. Long-term revolver borrowings declined to $154.3 million from $223.0 million, and the company remained in compliance with credit covenants. Shares outstanding were 18,483,271 as of October 28, 2025.
Addus HomeCare Corporation furnished a Form 8-K announcing its results of operations for the fiscal quarter ended September 30, 2025. The company disclosed this through a press release attached as Exhibit 99.1, which is incorporated by reference.
The filing confirms the announcement date of November 3, 2025 and lists the company’s common stock trading as ADUS on The Nasdaq Stock Market. Detailed financial and operational results are presented in the attached press release.
Heather Brianne Dixon, a named officer of Addus HomeCare Corp (ADUS), reported an acquisition on 09/15/2025 of 28,370 shares of the issuer's common stock at a reported price of $0. Following the reported transaction, Ms. Dixon beneficially owns 32,189 shares, held directly. The filing includes an explanatory note that the newly reported shares vest in equal installments on September 15, 2026, September 15, 2027, and September 15, 2028, subject to customary continued-service provisions and acceleration on a change in control. The Form 4 was signed by an attorney-in-fact on 09/16/2025.
Addus HomeCare Corp (ADUS) Form 3: Heather Brianne Dixon, listed at 6303 Cowboys Way, Suite 600, Frisco, TX 75034, filed an initial Section 16 beneficial ownership statement reporting 3,819 shares of Common Stock held directly. The Form 3 is dated for the event on 09/15/2025 and was signed by an attorney-in-fact on 09/16/2025. Her relationship to the issuer is shown as an Officer (President and Chief Operating).
Addus HomeCare Corp. (ADUS) insider filing shows W. Bradley Bickham, the company's President and COO, reported a sale of 4,000 shares of common stock on 09/02/2025 at a weighted-average price of $115.75. After the sale he beneficially owned 37,605 shares. The Form 4 was filed as a single-person report and was signed by an attorney-in-fact for Mr. Bickham on 09/03/2025. The filing discloses the sale prices ranged from $115.48 to $116.14.
R. Dirk Allison, Chairman and CEO of Addus HomeCare (ADUS), reported multiple transactions on 09/02/2025. The filing shows acquisition of 25,000 shares via exercise of employee stock options at a $19.71 exercise price and two open-market disposals totaling 25,000 shares sold at weighted-average prices of $115.72 and $116.34. After these transactions the reporting person beneficially owned 166,461 shares directly. The filing notes all options are fully vested and provides weighted-average price ranges for the sales.
Addus HomeCare Corp. (ADUS) Form 144 shows a proposed sale of 4,000 common shares through Morgan Stanley Smith Barney on 09/02/2025 on NASDAQ, with an aggregate market value of $462,982.40 and 18,407,239 shares outstanding. The filing details that the shares were received as restricted stock in four grants between 03/02/2019 and 03/02/2022 totaling 4,000 shares. It also discloses a prior sale by the same person of 9,000 common shares on 08/13/2025 for gross proceeds of $1,038,105.91. The filer certifies no undisclosed material adverse information.
Addus HomeCare Corp. (ADUS) Form 144 notifies a proposed sale of 25,000 common shares by an identified seller through Morgan Stanley Smith Barney on Nasdaq with an aggregate market value of $2,895,722.50. The shares were acquired and are proposed to be sold on 09/02/2025 following a stock option exercise paid in cash. The filer also discloses a prior sale by the same person of 25,000 shares on 08/20/2025 for gross proceeds of $2,873,862.50. The notice includes the seller’s representation that they are not aware of undisclosed material adverse information about the issuer.
FAQ
What is the current stock price of Addus Homecare (ADUS)?
What is the market cap of Addus Homecare (ADUS)?
